Shandong Boan Biotechnology Co., Ltd. (Boan Biotech) disclosed that Executive Director, President of Research and Development and Chief Operating Officer Dr. Dou Changlin will retire upon reaching the statutory retirement age. His resignation, which also includes stepping down as chairman of the Strategy Committee, will take effect on 31 March 2026. Dr. Dou confirmed he has no disagreements with the Board and highlighted no other matters requiring shareholder attention. The Board acknowledged his diligent service and contributions to the Group’s growth.

\n\nEffective the same date, Chairlady and Executive Director Ms. Jiang Hua will assume the role of chairlady of the Strategy Committee, while Executive Director Mr. Wang Shenghan will join the committee as a member. Post-adjustment, the Strategy Committee will comprise Ms. Jiang Hua (chairlady), Mr. Wang Shenghan and Professor Shi Luwen.

\n\nAs of 31 March 2026, Boan Biotech’s Board composition is as follows: • Executive Directors: Ms. Jiang Hua, Mr. Wang Shenghan • Non-Executive Directors: Mr. Liu Yuanchong, Ms. Li Li, Mr. Li Shixu • Independent Non-Executive Directors: Professor Shi Luwen, Mr. Dai Jixiong, Dr. Yu Jialin

\n\nThe announcement contains no financial performance metrics or operational forecasts, focusing solely on leadership changes scheduled for 31 March 2026.